Skip to content

Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope

Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01981148
Acronym
FLIO-Group
Enrollment
892
Registered
2013-11-11
Start date
2013-02-01
Completion date
2025-12-31
Last updated
2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autofluorescence Imaging, Neuroimaging

Brief summary

Fluorescent lifetime microscopy has emerged as a useful tool to study fluorescent lifetimes in vitro. Fluorescence lifetime represents the average amount of time a fluorophore remains in the excited state following excitation and depends on the fluorophores molecular environment. Fluorescence lifetime ophthalmoscopy (FLIO) is a technique which can quantify fluorescence lifetimes in the human retina in vivo. The purpose of this study is to investigate fluorescence lifetime characteristics in the human retina by using a FLIO. The investigators hypothesize that FLIO will allow to identify areas of retinal metabolic stress such as ischemia by detecting changes in fluorescence lifetimes.

Detailed description

Background Ophthalmic imaging has made considerable progress in the last years. Especially the introduction of optical coherence tomography and the scanning laser ophthalmoscope has helped to understand the structural changes underlying various retinal diseases. However, the appearance of structural changes during retinal disease often represents irreversible functional loss with only limited treatment options. In order to prevent loss of vision, retinal diseases should ideally be diagnosed before structural changes occur. This can be achieved by imaging metabolic changes of the retina as most retinal diseases such as age related macular degeneration or diabetic retinopathy are associated with distinct metabolic changes, mainly related to oxidative stress. Recently, a novel device for imaging fluorescent lifetimes of the retina in vivo, the fluorescent lifetime ophthalmoscope (FLIO), has been developed. This device is able to measure fluorescence lifetimes in the retina on a macroscopic level and may be able to shed new light on metabolic diseases of the retina. Objective To define fluorescence lifetime characteristics in healthy patients and patients with various retinal diseases. Methods The investigators will use a novel device, the fluorescence lifetime ophthalmoscope (FLIO) to investigate fluorescence lifetimes in the human retina.

Interventions

DEVICEFluorescence lifetime ophthalmoscope

All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subject must be willing to give written informed consent * Healthy volunteers 18 years of age or greater * Patients 18 years of age or greater * No significant media opacities

Exclusion criteria

* Opacities of ocular media excluding detailed observation of the retina

Design outcomes

Primary

MeasureTime frameDescription
Fluorescence lifetime measured by a fluorescence lifetime imaging ophthalmoscopeat baselineMeasured by fluorescence lifetime variable (TAU). Measured once; in some patients, up to 4 measurements within 2 years will be done

Secondary

MeasureTime frameDescription
Repeatability of FLIOat baselineTwo independent measurements

Countries

Switzerland

Contacts

STUDY_CHAIRMartin Zinkernagel, Prof.Dr.Dr.

Inselspital, University Clinic Ophthalmology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026